CRISPR/Cas13d targeting GZMA in PARs pathway regulates the function of osteoclasts in chronic apical periodontitis

Cell Mol Biol Lett. 2023 Aug 25;28(1):70. doi: 10.1186/s11658-023-00477-2.

Abstract

Chronic apical periodontitis is a prevalent oral disease characterized by bone loss, and its underlying mechanisms remain unclear. This study aimed to investigate the role and mechanism of the serine protease GZMA in osteoclasts during chronic apical periodontitis. To address this, we employed crRNA/Cas13d to inhibit GZMA expression and examined its impact on osteoclast behavior. Our findings revealed that GZMA plays a significant role in promoting osteoclast cell proliferation while inhibiting cell apoptosis. Additionally, the inhibition of GZMA led to a notable increase in miR-25-3p expression, which, in turn, downregulated the expression of TGF-β. Consequently, the reduction in TGF-β expression led to a decrease in PAR1 expression within the PARs pathway. These results suggest that GZMA might serve as a promising therapeutic target for the treatment of chronic apical periodontitis. Furthermore, our study highlights the potential of targeting GZMA using crRNA/Cas13d as a valuable approach for future therapeutic interventions.

Keywords: CRISPR/Cas13d; Chronic apical periodontitis; GZMA; Osteoclast.

Publication types

  • Letter

MeSH terms

  • Apoptosis / genetics
  • Clustered Regularly Interspaced Short Palindromic Repeats*
  • Granzymes
  • Humans
  • Osteoclasts
  • Periapical Periodontitis* / genetics
  • RNA, Guide, CRISPR-Cas Systems
  • Transforming Growth Factor beta

Substances

  • RNA, Guide, CRISPR-Cas Systems
  • Transforming Growth Factor beta
  • GZMA protein, human
  • Granzymes